Battlefield Pain Management � Analgesic
Defense Health Agency · DEFENSE HEALTH AGENCY
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation HT942726RE009 in this department, oldest first.
- Apr 23, 2026 · this noticePre-solicitation
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Answer the notice: this is when the requirement can still be shaped.
- Contact the contracting officer named on the notice.
- Check who won similar work; they are the likely bidders.
What the notice says
The Defense Health Agency Contracting Activity (DHACA), Research & Development Contracting Division 2, intends to issue a Request for Prototype Proposal (RPP) on behalf of the Operational Medical Systems, Warfighter Protection and Acute Care Project Management Office for Battlefield Pain Management � Analgesic. The intent is to issue a competitive RPP for the development of an analgesic product with a moderate to severe pain indication through the Food and Drug Administration approval for use on the battlefield, at the point of injury, during Tactical Combat Casualty Care, and/or during Prolon… (show all)
ged Casualty Care. The proposal will be open to any analgesic product, including combination products, to ensure that competition and innovation will be maximized. Subject to the availability of funds and evolving Government requirements, multiple awards may be made for the development of up to two products, with an Emergency Use Authorization as a potential strategy for early delivery to the Warfighter. DHACA intends to publish the RPP in Quarter 3 � Quarter 4, Fiscal Year 2026 with up to two awards expected to be delivered in Quarter 1 � Quarter 2, Fiscal Year 2027. No telephone calls will be accepted.
Who won similar work
5 award notices on SAM.gov in the last 24 months. Matched by: Same agency (Defense Health Agency), same NAICS 541714.
Single-winner award sizes (5): middle half $273K to $11.5M, median $2.0M; range $110K to $72.4M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| CHENEGA SERVICES & FEDERAL SOLUTIONS, LLC | 1 | $72.4M | May 20, 2026 |
| CHENEGA PROFESSIONAL & TECHNICAL SERVICES LLC | 1 | $11.5M | Sep 29, 2025 |
| MAPP BIOPHARMACEUTICAL, INC. | 1 | $2.0M | Jun 4, 2025 |
| ILLUMINA, INC. · $ILMN · $4.5B | 1 | $273K | May 30, 2026 |
| POTOMAC AFFINITY PROTEINS, LLC | 1 | $110K | Jul 9, 2025 |
Value counts new single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling (same contract, or the same office, day and amount); that ceiling is not one company's win, so it is not added in. Contract modifications are not new awards and are not added in either. Revenue next to a ticker is the company's revenue over the latest 12 months in its SEC filings.
- $ILMN reported $4.5B revenue (12 months to Jun 28, 2026). The median single-winner award in these 5 past awards, $2.0M, is under 0.1% of that. SEC filing
One award's total value against one year of revenue; many awards are paid over several years.
- May 30, 2026ILLUMINA, INC.$273KIllumina Urinary Pathogen Identification (ID)/Antimicrobial Resistance (AMR) Enrichment Kit (UPIP), (1) Respiratory Pathogen ID/AMR Enrichment Kit Set A,Materiality: <0.01% of $ILMN revenue (Low) SEC
- May 20, 2026CHENEGA SERVICES & FEDERAL SOLUTIONS, LLC$72.4MScientific, Technical Research and Project Management Support Services for USAMRIIDNo listed company matched (Materiality N/A)
- Sep 29, 2025CHENEGA PROFESSIONAL & TECHNICAL SERVICES LLC$11.5MScientific and Technical Research Support ServicesNo listed company matched (Materiality N/A)
- Jul 9, 2025POTOMAC AFFINITY PROTEINS, LLC$110KUsing Protease Cascades to Detect Protein TargetsNo listed company matched (Materiality N/A)
- Jun 4, 2025MAPP BIOPHARMACEUTICAL, INC.$2.0Mhuman-derived monoclonal antibodies (mAbs) and viral recombinant antigens (Ags)No listed company matched (Materiality N/A)
Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.
Competitive landscape
For the 5 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 1 of these past winners lobbied Defense, Dept of (DOD) or Office of the Secretary of Defense or Joint Chiefs of Staff since 2024 (1 filings)
- 0 of their lobbyists list a past Defense, Dept of (DOD) or Office of the Secretary of Defense or Joint Chiefs of Staff job
- No corporate PAC money from them to the overseeing committees since 2024
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 1 bills named on the past winners' lobbying filings
- 32 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 1 of the past winners are listed companies
- 0 insider buys and 4 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name, including the subsidiaries a company lists in its SEC filings. A company we could not match shows no market rows; that is a miss, not a finding.